KOKOWA
2021-08-27
👍
Why Zomedica Stock Is Zooming Higher Today
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
4
6
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":819310400,"tweetId":"819310400","gmtCreate":1630033330200,"gmtModify":1704954926874,"author":{"id":3557704604168397,"idStr":"3557704604168397","authorId":3557704604168397,"authorIdStr":"3557704604168397","name":"KOKOWA","avatar":"https://static.tigerbbs.com/eeff56eeb7ebce5a55608cef0cd0bfae","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":9,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":187,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>👍</p></body></html>","htmlText":"<html><head></head><body><p>👍</p></body></html>","text":"👍","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":4,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/819310400","repostId":1122548190,"repostType":4,"repost":{"id":"1122548190","kind":"news","pubTimestamp":1630031791,"share":"https://www.laohu8.com/m/news/1122548190?lang=&edition=full","pubTime":"2021-08-27 10:36","market":"us","language":"en","title":"Why Zomedica Stock Is Zooming Higher Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1122548190","media":"Motley Fool","summary":"Key Points\n\nThere wasn't any news from Zomedica to serve as a catalyst.\nToday's gain appears to be c","content":"<p>Key Points</p>\n<ul>\n <li>There wasn't any news from Zomedica to serve as a catalyst.</li>\n <li>Today's gain appears to be continued momentum related to an SEC filing made earlier this week by Morgan Stanley.</li>\n</ul>\n<p>What happened</p>\n<p>Shares of <b>Zomedica</b>(NYSEMKT:ZOM)were zooming 16.7% higher as of 11:40 a.m. EDT on Thursday after soaring as much as 37.9% earlier in the session. There wasn't any news from the company, though.</p>\n<p>Instead, today's big gain appears to be a continuation of momentum from earlier this week following a filing<b>Morgan Stanley</b>(NYSE:MS)made with the U.S. Securities and Exchange Commission. That SEC filing revealed that Morgan Stanley had invested more than $1.6 million in Zomedica stock.</p>\n<p>So what</p>\n<p>It's good news that a major investment bank thinks highly enough of Zomedica that it's buying the animalhealthcare stock. However, some context might be helpful. Morgan Stanley bought a little under 2 million shares. That's barely 0.2% of Zomedica's outstanding shares.</p>\n<p>Buying Zomedica just because Morgan Stanley did isn't a prudent move. On the other hand, investing because the business fundamentals could improve significantly in the future can be a good reason to buy a stock.</p>\n<p>In this case, there are reasons to think that Zomedica's business could pick up relatively soon. The big question for investors, though, is whether sales will increase enough to justify the company's market cap of close to $500 million.</p>\n<p>Now what</p>\n<p>Zomedica expects that its fT4 assay for veterinarians to diagnose potential thyroid problems in animals will be available this fall. The company hopes its ACTH assay for testing animals' cortisol levels will be on the market by the end of the year. The rollouts of these assays could boost sales for Zomedica's Truforma diagnostic instruments.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Zomedica Stock Is Zooming Higher Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Zomedica Stock Is Zooming Higher Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 10:36 GMT+8 <a href=https://www.fool.com/investing/2021/08/26/why-zomedica-stock-is-zooming-higher-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nThere wasn't any news from Zomedica to serve as a catalyst.\nToday's gain appears to be continued momentum related to an SEC filing made earlier this week by Morgan Stanley.\n\nWhat happened\n...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/26/why-zomedica-stock-is-zooming-higher-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZOM":"Zomedica Pharmaceuticals Corp."},"source_url":"https://www.fool.com/investing/2021/08/26/why-zomedica-stock-is-zooming-higher-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122548190","content_text":"Key Points\n\nThere wasn't any news from Zomedica to serve as a catalyst.\nToday's gain appears to be continued momentum related to an SEC filing made earlier this week by Morgan Stanley.\n\nWhat happened\nShares of Zomedica(NYSEMKT:ZOM)were zooming 16.7% higher as of 11:40 a.m. EDT on Thursday after soaring as much as 37.9% earlier in the session. There wasn't any news from the company, though.\nInstead, today's big gain appears to be a continuation of momentum from earlier this week following a filingMorgan Stanley(NYSE:MS)made with the U.S. Securities and Exchange Commission. That SEC filing revealed that Morgan Stanley had invested more than $1.6 million in Zomedica stock.\nSo what\nIt's good news that a major investment bank thinks highly enough of Zomedica that it's buying the animalhealthcare stock. However, some context might be helpful. Morgan Stanley bought a little under 2 million shares. That's barely 0.2% of Zomedica's outstanding shares.\nBuying Zomedica just because Morgan Stanley did isn't a prudent move. On the other hand, investing because the business fundamentals could improve significantly in the future can be a good reason to buy a stock.\nIn this case, there are reasons to think that Zomedica's business could pick up relatively soon. The big question for investors, though, is whether sales will increase enough to justify the company's market cap of close to $500 million.\nNow what\nZomedica expects that its fT4 assay for veterinarians to diagnose potential thyroid problems in animals will be available this fall. The company hopes its ACTH assay for testing animals' cortisol levels will be on the market by the end of the year. The rollouts of these assays could boost sales for Zomedica's Truforma diagnostic instruments.","news_type":1},"isVote":1,"tweetType":1,"viewCount":257,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/819310400"}
精彩评论